Chris Takimoto, MD, PhD, FACP

Dr. Takimoto is the Chief Medical Officer of IGM Biosciences. Dr. Takimoto has 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences. Prior to Gilead, Dr. Takimoto was Chief Medical Officer of Forty Seven, a biotechnology company formed out of Stanford University and acquired by Gilead Sciences in 2020. Dr. Takimoto has also served as Vice President of Experimental Medicine Early Development, Oncology Therapeutic Area for Janssen Research and Development. Prior to Janssen, Dr. Takimoto was Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development. He has over thirty years of experience in industry and academia, including academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute, and the Uniformed Services University of the Health Sciences. He has also served as a Commissioned Officer in the U.S. Public Health Service. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University, and an M.D. from Yale University School of Medicine.